Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of JR-401 in pediatric short stature with SHOX deficiency
jRCT2031200425Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somatropin in SHOX deficiency disorder and SHOX haploinsufficiency, sponsored by JCR Pharmaceuticals. Primary endpoint: Safety and efficacy during long-term administration. Started Sep 2020; status: completed.
02
Drugs
somatropin
03
Conditions
SHOX deficiency disorderSHOX haploinsufficiency
Beyond the preview
Go deeper on jRCT2031200425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200425.